Relafen Labeling Revision Includes Stronger Renal Effects Precaution
Executive Summary
The maximum starting dose of GlaxoSmithKline's Relafen in patients with moderate to severe renal insufficiency should not exceed 750 mg or 500 mg, respectively, according to revised labeling for the nonsteroidal anti-inflammatory drug